Leo Pharma Delays IPO Beyond 2026 as Market Conditions Stay Volatile

The Danish skin-disease drugmaker has put off its planned public listing until after this year, with Chief Executive Christophe Bourdon blaming turbulent markets for the hold-up.
Leo Pharma AS headquarters near Copenhagen. Leo Pharma AS headquarters near Copenhagen.
Source: LEO Pharma

Leo Pharma A/S has pushed back plans for an initial public offering beyond 2026, becoming the latest European drugmaker to shelve a listing because of unsettled equity markets.

The Danish company, which focuses on treatments for skin conditions such as psoriasis and eczema, had previously aimed to go public this year. Chief Executive Officer Christophe Bourdon said the business is operationally ready for a market debut, but that volatility has made 2026 the wrong moment.

IPO window narrows

European listings have faced a tougher environment in 2026 as investors pull back from riskier assets and interest-rate uncertainty continues to rattle valuations. Healthcare companies have been especially exposed, because their stock prices depend heavily on long-term growth assumptions that look less attractive when borrowing costs stay elevated.

For Leo Pharma, the delay means its private-equity owners will have to wait longer for an exit. The company was taken private by a consortium including Advent International, Auven Therapeutics and Novo Holdings in a deal worth about $3.5 billion in 2015.

Pipeline progress continues

Despite the postponement, Bourdon emphasized that the company has made progress on its drug pipeline and commercial operations. Leo Pharma has been expanding its portfolio beyond established dermatology brands and investing in biologic therapies for inflammatory skin diseases.

Investors had been watching the IPO closely as a signal of whether European biotechnology and specialty-pharma companies could return to public markets after a quiet period. Leo Pharma's decision suggests that executives remain cautious about demand from institutional buyers.

Broader European trend

The delay fits a wider pattern across the continent, where companies that were expected to list in 2026 have either reduced their valuations or pulled their offerings entirely. Volatility in global markets, driven in part by shifting trade policies and geopolitical tension, has made underwriting new issues more expensive and unpredictable.

Leo Pharma has not set a new target date for the listing. Bourdon indicated that the company will revisit the timing when conditions improve, leaving the door open for a 2027 debut if sentiment stabilizes.

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Terms of Use